Publication: 794

The anti-CD80 primatized monoclonal antibody, galiximab, is well-tolerated but has limited activity in relapsed Hodgkin lymphoma: Cancer and Leukemia Group B 50602 (Alliance)
      QxMD      Google Scholar   
Citation:
Leuk Lymphoma vol 54 (7) 1405-1410
Year:
2013
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
2
Parents:
354  
Children:
None
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
CA33601, CA77597, CA41287, U10 CA031946, CA77651, U10 CA033601, CA77440, (CA31946  
Corr. Author:
 
Authors:
             
Networks:
CAPITAL, LAPS-IL057, LAPS-MO011, LAPS-NY016   
Study
CALGB-50602
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Hodgkin lymphoma, galiximab, CD80, clinical trial